Evaluation of Antifungal Susceptibility Testing with Microdilution and Etest Methods of Candida Blood Isolates

Mycopathologia

Volumn 172, Issue 3, 2011, Pages 187-199

  Metin, Dilek Yesim ^a   Hilmioglu Polat, Suleyha ^a   Samlioglu, Pinar ^a   Doganay Oflazoglu, Biray ^a   Inci, Ramazan ^a   Tumbay, Emel ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amphotericin B; Candida; Etest; Fluconazole; Itraconazole; Microdilution; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; BLOOD; CANDIDA; CANDIDEMIA; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; BLOOD; CANDIDA; CANDIDEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS;

EID: 79960699044     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9413-y     Document Type: Article

References (45)

1. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007; 60: 424-8.
2. Mercedes Panizo M, Reviakina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2008; 24: 1-7.
3. Negri M, Martins M, Henriques M, Svidzinski TI, Azeredo J, Oliveira R. Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycopathologia. 2010; 169: 175-82.
4. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8. 5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007; 45: 1735-45.
5. Lu JJ, Lee SY, Chiueh TS. In vitro antifungal susceptibility testing of Candida blood isolates and evaluation of the E-test method. J Microbiol Immunol Infect. 2004; 37: 335-42.
6. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003; 47: 3149-54.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard, NCCLS document M27-A2. 2nd ed. Wayne: National Committee for Clinical Laboratory standards; 2002.
8. Yapar N, Uysal U, Yucesoy M, Cakir N, Yuce A. Nosocomial bloodstream infection associated with Candida species in a Turkish University Hospital. Mycoses. 2006; 49: 134-8.
9. Aydin F, Bayramoglu G, Guler NC, Kaklikkaya N, Tosun I. Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey. Med Mycol. 2010; 1-4 (early online).
10. Kiraz N, Oz Y. Species distribution and in vitro antifungal susceptibility of clinical Candida isolates from a university hospital in Turkey over a 5-year period. Med Mycol. 2010; 1-6 (early online).
11. Huseyin A, Sancak B, Arikan S. In vitro activity of amphotericin B, fluconazole, and itraconazole against Candida glabrata strains isolated from clinical samples. Mikrobiyol Bul. 2007; 41: 235-44.
12. Ozcan SK, Mutlu B, Dundar D, Willke A. Comparison of broth microdilution and Etest methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures. Mikrobiyol Bul. 2010; 44: 263-71.
13. Saracli MA, Gumral R, Gul HC, Gonlum A, Yildiran ST. Species distribution and in vitro susceptibility of Candida bloodstream isolates to six new and current antifungal agents in a Turkish tertiary care military hospital, recovered through 2001 and 2006. Mil Med. 2009; 174: 860-5.
14. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol. 2007; 56: 255-9.
15. González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol. 2008; 46: 2902-5.
16. Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility testing of Candida isolates from the Surveillance Study (CaSS). J Clin Microbiol. 2010; 48: 1270-5.
17. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007; 59: 767-71.
18. Alp S, Sancak B, Ari{dotless}kan S. Determination of in vitro susceptibility of Candida species to amphotericin B by Etest and previously proposed MIC breakpoints on two different media. Mikrobiyol Bul. 2008; 42: 293-300.
19. Godoy P, Tiraboschi IN, Severo LC, Bustamante B, Calvo B, Almeida LP, da Matta DA, Colombo AL. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz, Rio de Janeiro. 2003; 98: 401-5.
20. Da Matta DA, de Almeida LP, Machado AM, Azevedo AC, Kusano EJ, Travassos NF, Salomão R, Colombo AL. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis. 2007; 57: 399-404.
21. Pfaller MA, Messer SA, Hollis RJ. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis. 1994; 20: 127-33.
22. Chiu YS, Chang SC, Hsueh PR, Wang JL, Sun HY, Chen YC. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest. J Microbiol Immunol Infect. 2006; 39: 335-41.
23. Passos XS, Costa CR, Araújo CR, Nascimento ES, e Souza LK, Fernandes Ode F, Sales WS, Silva Mdo R. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia. 2007; 163: 145-51.
24. Colombo AL, Da Matta D, De Almeida LP, Rosas R. Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method. Braz J Infect Dis. 2002; 6: 118-23.
25. Antunes AG, Pasqualotto AC, Diaz MC, d'Azevedo PA, Severo LC. Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Inst Med Trop Sao Paulo. 2004; 46: 239-41.
26. Maxwell MJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Diekema DJ, Pfaller MA. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41: 1087-90.
27. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, Lee WG, Lee HS, Chang CL, Kim SH, Shin MG, Suh SP, Ryang DW. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J. 2007; 48: 779-86.
28. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1, 586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol. 2003; 41: 1440-6.
29. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol. 2003; 41: 1875-80.
30. Samra Z, Yardeni M, Peled N, Bishara J. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur J Clin Microbiol Infect Dis. 2005; 24: 592-5.
31. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50: 2009-15.
32. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004; 53: 283-9.
33. Lass-Flörl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008; 52: 3637-41.
34. Linares MJ, Charriel G, Solís F, Casal M. Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole. J Clin Microbiol. 2004; 42: 899-902.
35. Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents. 2005; 25: 321-8.
36. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13, 338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol. 2007; 45: 70-5.
37. Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR, Reller LB. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol. 2007; 45: 698-706.
38. Martin-Mazuelos E, Gutiérrez MJ, Aller AI, Bernal S, Martínez MA, Montero O, Quindós G. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp. J Antimicrob Chemother. 1999; 43: 477-81.
39. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 2002; 46: 1781-4.
40. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol. 1995; 33: 535-40.
41. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 2003; 47: 1647-51.
42. Chang HC, Chang JJ, Chan SH, Huang AH, Wu TL, Lin MC, Chang TC. Evaluation of Etest for direct antifungal susceptibility testing of yeasts in positive blood cultures. J Clin Microbiol. 2001; 39: 1328-33.
43. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J Clin Microbiol. 2001; 39: 4181-3.
44. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standarts broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphoterisin B-resistant Candida isolates. Antimicrob Agents Chemother. 1995; 39: 2520-2.
45. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001; 14: 643-58.